CClinicalTrials.gg
Sign In
WithdrawnNCT04903054Updated Mar 22, 2023

Selective CD28 Blockade in Renal Transplant Recipients

A Phase 2 interventional study of Lulizumab and Tacrolimus in Kidney Transplantation and Renal Transplant Recipients, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Withdrawn at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-03-22.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Limited period of availability of a supply of the study drug and difficulties in enrollment
Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The aim of this study is to evaluate the safety and efficacy of lulizumab, a CD28-specific domain antibody (CD28 dAb), compared to tacrolimus, as the primary immunosuppressant in first-time renal transplant recipients.

Read the detailed description

This is a phase 2a, open-label, prospective, randomized (1:1), controlled, single center study evaluating the safety and efficacy of lulizumab (a CD28 specific domain antibody [CD28dAb]) compared to tacrolimus as the primary immunosuppressant in first-time renal transplant recipients. The study will take place at Emory University Hospital in Atlanta, Georgia, United States (US).

There are two arms/groups in this study, the Control (tacrolimus) group and the Investigational (lulizumab) group. The two arms will be assigned to treatment regimens for the first 12 months after transplantation; at that point, all participants in each arm will be transitioned to a physician directed Standard of Care (SOC) immunosuppressive regimen, and all participants will be assessed at 15 months after transplantation.

All participants will receive induction therapy with Thymoglobulin and Methylprednisolone and maintenance therapy with Mycophenolate Mofetil (MMF) and Prednisone.

02

Conditions studied

  • Kidney Transplantation
  • Renal Transplant Recipients

Keywords

  • CD28 blockade
  • Cluster of Differentiation (CD)
  • CNI inhibition
  • immune modulation
  • rejection
03

In context

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,401 studies on the registry; 179 are open to participants now.

Of its 396 completed or terminated interventional studies of FDA-regulated products, 294 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Individuals who meet all of the following criteria are eligible for enrollment as study participants:

  1. Must be able to understand and provide informed consent;
  2. Negative crossmatch (actual or virtual) or a Panel Reactive Antibody (PRA) of 0% on historic and admission sera;
  3. First time renal transplant from either a living or deceased donor;
  4. Deceased donor recipients only: Deceased donor kidneys with Kidney Donor Profile Indices (KDPI) \<85%;
  5. Female study participants of childbearing potential must have a negative pregnancy test prior to randomization;

  6. Agreement to use contraception; according to the Food and Drug Administration (FDA) Office of Women's Health (http://www.fda.gov/birthcontrol), there are a number of birth control methods that are more than 80 percent effective.

    --Female study participants of child-bearing potential and male study participants must consult with their physician and determine the most suitable method(s) from this list to be used from the time that study treatment begins until after study completion;

  7. Study participants must have a negative purified protein derivative (PPD) or negative testing for tuberculosis using an approved interferon-gamma release assay (IGRA) blood test, such as:

    • QuantiFERON®-TB Gold In-Tube test (QFT-GIT) or
    • TSPOT® TB test ---PPD or IGRA testing must be documented to have been performed within 52 weeks before transplant;
  8. Documented completion of varicella vaccination series ≥ 8 weeks prior to enrollment, OR verification of a history of varicella or zoster by a physician OR positive laboratory confirmation of varicella immunity or disease; and,
  9. Immunizations are up-to-date based on the CDC° adult vaccination recommendations:

https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html

--°Centers for Disease Control and Prevention (CDC)

Exclusion criteria

Exclusion Criteria:

Individuals who meet any of these criteria are not eligible for enrollment as study participants:

  1. Inability or unwillingness of a study participant to give written informed consent or comply with study protocol;
  2. Recipient of previous organ transplant of any type;
  3. Need for multi-organ transplant;
  4. Calculated panel reactive antibody (cPRA) or panel reactive antibody (PRA) >20% at any time prior to enrollment;
  5. Known hypersensitivity to mycophenolate mofetil (MMF) or any of the drug's components;
  6. Human immunodeficiency virus (HIV): individuals known to be HIV positive;
  7. Known history of Bacillus Calmette-Guérin (BCG) vaccination;

  8. Individuals at significant risk of early recurrence of the primary renal disease including: -Focal Segmental Glomerulosclerosis (FSGS)

    • Membranoproliferative Glomerulonephropathy (MPGN) type 2
    • Hemolytic Uremia Syndrome/Thrombotic thrombocytopenic purpura (HUS/TTP), or
    • any other disease that, in the opinion of the investigator, is at increased likelihood of recurrence and which may result in rapid decline in renal function

  9. Known history of high-risk thrombotic events or risk factors; including any of the following:

    • Factor V Leiden, elevated homocysteine, positive lupus anticoagulant, elevated anticardiolipin antibody, heparin induced thrombocytopenia
    • A family history of a heritable thrombotic condition
    • Recurrent Deep vein thrombosis (DVT) or Pulmonary Embolism (PE), or
    • Unexplained stillborn infant or recurrent spontaneous abortion of other congenital or acquired thrombotic disorder

  10. History of malignancy within 5 years of enrollment or any history of hematogenous malignancy or lymphoma.

    --Note: Study participants with curatively treated non-melanomatous skin cancer or curatively treated cervical carcinoma in situ may be enrolled;

  11. Study participants who are on biologic treatments for autoimmune disease;
  12. Study participants who are involuntarily detained (e.g. prison, jail, compulsory psychiatric or medical therapy);

  13. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator:

    • May pose additional risks from participation in the study,
    • May interfere with the study participant's ability to comply with study requirements, or
    • May impact the quality or interpretation of the data obtained from the study;
  14. Human leukocyte antigen (HLA) identical donor/recipient pairing;
  15. Use of investigational drugs within 4 weeks of transplant;

  16. Study participants who are NOT Epstein-Barr virus (EBV) seropositive

    -A prior documented EBV seropositive result at enrollment does not need to be repeated --For this study, EBV seropositive patients are defined as having evidence of acquired immunity shown by the presence of immunoglobulin G (IgG) antibodies to viral capsid antigen (VCA) and the presence of antibodies to EBV nuclear antigen (EBNA or EBNA1);

  17. Hepatitis C virus (HCV): Study participants who are HCV RNA PCR positive at prerandomization re-evaluation

    -Study participants who are seropositive must have 2 consecutive negative HCV RNA PCR at least 24 weeks apart;

  18. Hepatitis B virus: Individuals with any of the following are NOT eligible:

    • Recipient or donor positive for hepatitis B surface antigen (HBsAg)
    • Recipient or donor with antibodies to hepatitis B core antigen (anti-HBc)
    • Recipient or donor with HBV DNA detectable by PCR;
  19. Recipient of a live or live-attenuated vaccine within 8 weeks prior to transplant;
  20. Cytomegalovirus (CMV) seronegative individuals accepting an organ from a CMV seropositive donor;

  21. Study participants undergoing transplant using:

    • Organs from donation after circulatory death (DCD) donor
    • Donor with Kidney Donor Profile Index (KDPI) >85%, or
    • Anticipated cold ischemia time >28 hours; or,
  22. ABO incompatible donor kidney.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Lulizumab + SOC

    N=27 participants will receive a loading dose of lulizumab on Day 0, the day of surgery. This will be followed by a maintenance dose administered on a weekly basis (weeks 1 through 26 post-transplant), followed by administration every two weeks (weeks 28 through 52 post-transplant). Method of administration: subcutaneously. Dose unit of measure: milligrams (mgs). Plus (+) Standard of Care (SOC) Regimen, per protocol- Renal transplant recipients will receive FDA-approved, immunosuppressive medications according to standard of care at Emory Transplant Center: * Induction Thymoglobulin: Administered intravenously, dose unit of measure: mgs. * Induction Methylprednisolone: Administered intravenously, dose unit of measure: mgs. * Maintenance: Mycophenolate mofetil (MMF) administered by mouth twice daily, dose unit of measure: mgs. * Maintenance: Beginning the day after methylprednisolone is completed, prednisone will be administered by mouth daily, dose unit of measure: mgs.

    Biological: Lulizumab · Biological: Thymoglobulin® · Drug: Methylprednisolone · Drug: Mycophenolate Mofetil · Drug: Prednisone

  • Active comparator
    Tacrolimus + SOC

    N=27 participants will receive tacrolimus initiated according to local standard of care and adjusted over time (maintenance) to target optimal trough levels measured in ng/mL: 0 to 6 months, 7 to 12 months and, thereafter, until completion of study participation. Dose unit of measure: mg/kg. Plus (+) Standard of Care (SOC) Regimen, per protocol- Renal transplant recipients will receive FDA-approved, immunosuppressive medications according to standard of care at Emory Transplant Center: * Induction Thymoglobulin: Administered intravenously, dose unit of measure: mgs. * Induction Methylprednisolone: Administered intravenously, dose unit of measure: mgs. * Maintenance: Mycophenolate mofetil (MMF) administered by mouth twice daily, dose unit of measure: mgs. * Maintenance: Beginning the day after methylprednisolone is completed, prednisone will be administered by mouth daily, dose unit of measure: mgs.

    Drug: Tacrolimus · Biological: Thymoglobulin® · Drug: Methylprednisolone · Drug: Mycophenolate Mofetil · Drug: Prednisone

Interventions

  • BiologicalLulizumab

    Lulizumab is a pegylated, humanized monovalent domain antibody construct that is specific for human cluster of differentiation CD28.

    Also known as: BMS-931699, anti-CD28 domain antibody (anti-CD28 dAb)

  • DrugTacrolimus

    Standard of Care: Renal transplant rejection prophylaxis.

    Also known as: Prograf®

  • BiologicalThymoglobulin®

    Standard of Care: Renal transplant rejection prophylaxis.

    Also known as: antithymocyte globulin

  • DrugMethylprednisolone

    Standard of Care: Renal transplant rejection prophylaxis.

    Also known as: corticosteroid

  • DrugMycophenolate Mofetil

    Standard of Care: Renal transplant rejection prophylaxis.

    Also known as: MMF, CellCept®

  • DrugPrednisone

    Standard of Care: Renal transplant rejection prophylaxis.

    Also known as: corticosteroid

06

What researchers measure

Primary outcomes

  1. Mean Estimated Glomerular Filtration rate (eGFR) (MDRD)

    Efficacy measure. Glomerular Filtration Rate (GFR) will be estimated using the Modification of Diet in Renal Disease (MDRD) equation. MDRD is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and gender.

    Time frame: From Month 2 to Month 12 Post Transplantation

Secondary outcomes

  1. Proportion of Participants Who Remain Free of Biopsy Proven Acute T-Cell Mediated Rejection (aTCMR)

    Safety measure. Defined by Banff 2017 kidney criteria. Reference: Haas, M. et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 18(2):293-307.

    Time frame: Up to 15 Months Post Transplantation

  2. Proportion of Participants Who Remain Free of Antibody-Mediated Rejection (ABMR)

    Safety measure. Defined by Banff 2017 kidney criteria. Reference: Haas, M. et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 18(2):293-307.

    Time frame: Up to 15 Months Post Transplantation

  3. Cumulative Incidence of Serious Adverse Events

    Safety measure.

    Time frame: Up to 15 Months Post Transplantation

  4. Incidence of Serious Infection(s) of Special Interest

    Safety measure. Definition: The occurrence of infection(s) requiring participant hospitalization or prolonged therapy, including but not limited to treatment ≥20 days.

    Time frame: Up to 15 Months Post Transplantation

  5. Incidence of Cytomegalovirus (CMV) Viremia

    Safety measure.

    Time frame: Up to 15 Months Post Transplantation

  6. Incidence of BK Polyoma Virus (BKV) Viremia

    Safety measure.

    Time frame: Up to 15 Months Post Transplantation

  7. Incidence of Any Malignancy, Including but Not Limited to PTLD

    Safety measure. Definitions: * Malignancy: A term for diseases in which abnormal cells divide without control and can invade nearby tissues. * Post-transplant Lymphoproliferative Disorder (PTLD) : A rare but well-known complication of solid organ transplants and hematopoietic stem cell transplantation.

    Time frame: Up to 15 Months Post Transplantation

  8. Proportion of Participants Experiencing the Composite Outcome of Death or Allograft Failure

    Efficacy measure.

    Time frame: Up to 15 Months Post Transplantation

  9. Proportion of Participants with Biopsy Proven Acute T-cell Mediated Cellular Rejection (BPaTCMR)

    Efficacy measure. Defined by Banff 2017 kidney criteria. Reference: Haas, M. et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 18(2):293-307.

    Time frame: Up to 15 Months Post Transplantation

  10. Proportion of Participants Treated for Kidney Transplant Rejection

    Efficacy measure. Definition: Participant requiring treatment for rejection with corticosteroids, T-cell depleting therapy, and/or any other treatment for kidney transplant rejection.

    Time frame: Up to 15 Months Post Transplantation

  11. Proportion of Participants Treated for Acute Rejection Due to Clinical Suspicion

    Efficacy measure. Acute rejection due to a clinical suspicion rather than BPaTCMR or BP-aABMR. Definitions: * BPaTCMR: Biopsy proven acute T-cell mediated cellular rejection * BP-aABMR: Biopsy proven active antibody mediated rejection

    Time frame: Up to 15 Months Post Transplantation

  12. Proportion of Participants with Biopsy Proven Active Antibody Mediated Rejection (BP-aABMR)

    Efficacy measure. Defined by Banff 2017 kidney criteria. Reference: Haas, M. et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 18(2):293-307.

    Time frame: Up to 15 Months Post Transplantation

  13. Proportion of Participants with aTCMR Changes in Allograft Biopsies

    Efficacy measure. Definitions: * aTCMR:acute T-cell mediated cellular rejection * Defined by Banff 2017 kidney criteria. Reference: Haas, M. et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 18(2):293-307.

    Time frame: Up to 15 Months Post Transplantation

  14. Time to Event for aTCMR Changes in Allograft Biopsies

    Efficacy measure. Definitions: * aTCMR:acute T-cell mediated cellular rejection * Defined by Banff 2017 kidney criteria. Reference: Haas, M. et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 18(2):293-307.

    Time frame: Up to 15 Months Post Transplantation

  15. Proportion of Participant Who Develop De-Novo Donor Specific Antibody

    Efficacy measure.

    Time frame: Up to 15 Months Post Transplantation

  16. Change in Estimated Glomerular Filtration Rate (eGFR)

    Efficacy measure. Glomerular Filtration Rate (GFR) will be estimated using the Modification of Diet in Renal Disease (MDRD) equation. MDRD is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and gender.

    Time frame: From Month 2 to Month 15 Post Transplantation

  17. Proportion of Participants with Delayed Graft Function

    Efficacy measure.

    Time frame: Within 1 Month Post Transplantation

  18. Hemoglobin A1C

    Efficacy measure. Definition: HbA1c: Glycosylated hemoglobin, a measure of the average plasma concentration of blood sugar (glucose) over the previous three months.

    Time frame: Month 12 Post Transplantation

  19. Days to Event: TCMR

    Efficacy measure. TCMR: T-cell mediated rejection.

    Time frame: Up to 15 Months Post Transplantation

  20. Days to Event: Antibody mediated rejection (ABMR)

    Efficacy measure. ABMR: Antibody mediated rejection.

    Time frame: Up to 15 Months Post Transplantation

  21. Days to Event: De-Novo Donor Specific Antibody (DSA) Formation

    Efficacy measure.

    Time frame: Up to 15 Months Post Transplantation

  22. Days to Event: Graft Loss

    Efficacy measure.

    Time frame: Up to 15 Months Post Transplantation

  23. Standardized Blood Pressure

    Efficacy measure.

    Time frame: Month 12 and Month 15 Post Transplantation

  24. Fasting Lipid Profile

    Efficacy measure. Included: Total cholesterol, LDL, HDL, and triglyceride.

    Time frame: Month 12 and Month 15 Post Transplantation

07

Study locations

1 site
  • Emory University Hospital
    Atlanta, Georgia 30332, United States
08

References and documents

Individual participant data

Plan to share: Yes — The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04903054
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Bristol-Myers Squibb, PPD DEVELOPMENT, LP
Responsible party
Sponsor
First posted
May 26, 2021
Start date
Jan 10, 2022
Primary completion
Sep 22, 2022
Completion
Sep 22, 2022
Last update
Mar 22, 2023

Study contacts

Christian P. Larsen, MD, DPhil
study chair · Emory Transplant Center, Emory University
Andrew B. Adams, MD, PhD
principal investigator · Emory Transplant Center, Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Start the discussion